GC
Therapeutic Areas
Ovid Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OV329 / TAK-935 (Soticlestat) | Dravet Syndrome, Lennox-Gastaut Syndrome | Phase 3 |
| OV350 | Angelman Syndrome (potential) | Preclinical |
| OV882 | Angelman Syndrome | Preclinical |
| OV815 | Undisclosed rare neurological target | Discovery |
Leadership Team at Ovid Therapeutics
AR
Amit Rakhit
President, Chief Executive Officer, and Chairman of the Board
TM
Thomas M. Perone
Chief Business Officer and General Counsel
JL
Jennifer L. Bath
Senior Vice President, Head of Program and Alliance Management
MB
Matthew B. During
Founder and Director
JM
Jeremy M. Levin
Lead Independent Director
RP
Robert Poole
Chief Financial Officer (Interim)
RD
Randy D. Hice
Senior Vice President, CMC & Technical Operations
MS
Matthew S. Harlow
Chief Operating Officer
RZ
Ralph Z. Sorenson
Director
MA
Meg Alexander
Director